Our people

Dr Robert Weinkove

Dr Robert Weinkove is a Consultant Haematologist at Wellington Blood & Cancer Centre and Clinical Director at the Malaghan Institute of Medical Research. His clinical and research interests are B-cell malignancies, cancer immunotherapy and innate-like T cells. He studied medicine at the University of Cambridge and Kings College London, trained in General Medicine and Haematology at Guy's and St Thomas' Hospitals in London and the Medizinische Hochschule Hannover in Germany, and completed an Immunology PhD in with the University of Otago. Dr Weinkove is a member of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group, and is working on a CAR-T cell programme in conjunction with Wellington Zhaotai Therapies Ltd and Guangzhou Institutes of Biomedicine and Health.

Research interests

Professor Ian Hermans, Vaccine Therapy Programme Leader, and Dr Robert Weinkove, Wade Thompson Clinical Research Fellow and Clinical Director of the Human Immunology Lab, are establishing a research group that will bring cutting-edge new cellular therapies into New Zealand. This research involves a breakthrough area of oncology called CAR-T cell immunotherapy.

In this transfusion-like therapy, some of the patient’s own immune cells, the ‘T cells’, are modified to express a specific receptor – a chimeric antigen receptor (CAR) – in order to redirect them against cancer cells. “The approach works differently to vaccines, which aim to boost someone’s own immune response,” explains Dr Weinkove. “Here, we’re directly altering the immune cells themselves to target them.”

Central to the success of this new translational research is the expertise and knowledge of our team in good manufacturing practice (GMP) – international regulations for the production of medicinal products. “Our collaborators have developed an exciting pipeline of CAR-T cell therapies, our role is to make changes to the way they are manufactured and trialled, so that it fits with what’s regarded in the Western regulatory environment as ‘best practise’,” Prof Hermans explained.

For us at the Malaghan Institute, the driving motivation behind this project is the impact that it could have on the lives of New Zealanders. “For some leukaemias, more than half of people treated with CAR-T cell therapies have remained in remission for years without any other treatment,” Dr Weinkove said. “This is preliminary data, and we still have questions about the longer term effects, but as a clinician, I am extremely excited about the potential of CAR-T cell therapies.”

Research group

Cancer Immunotherapy Programme
Cancer Immunotherapy Programme Leader: Professor Ian Hermans
Senior Research Fellow: Dr Olivier Gasser
Clinical Research Fellow: Dr Robert Weinkove
Research Fellow: Dr Laura Ferrer-Font
Senior Research Officer: Kathryn Farrand
Ching-Wen Tang
Astrid Authier-Hall
Research Officer: Dr Nathaniel Dasyam
PhD Student: Joshua Lange
Olivia Burn
Regan Fu
Kef Prasit
Ellie-May Jarvis
Clinical Trials
Clinical Director: Dr Robert Weinkove
Deputy Director of Research: Professor Ian Hermans
Clinical Research Fellow: Dr Philip George
GMP Manager: Dr Giulia Giunti
GMP Production Manager: Evelyn Bauer
Senior GMP Specialist: Dr Brigitta Mester
Clinical Trial Project Coordinator: Bethany Andrews
Research Officer: Kirsty Wakelin